Iressa (Gefitinib)

DRUG5 trials

Sponsors

Groupe Oncologie Radiotherapie Tete et Cou, AstraZeneca

Conditions

Brain NeoplasmsCarcinoma, Squamous CellHead and Neck CancerMetastatic Colorectal CancerNon Small Cell Lung CancerNon Small Cell Lung Carcinoma

Phase 2

Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas

TerminatedNCT00169221

Groupe Oncologie Radiotherapie Tete et CouHead and Neck Cancer

Start: 2005-09-30End: 2011-07-31Updated: 2011-11-15

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

WithdrawnNCT00233623

AstraZenecaMetastatic Colorectal Cancer

Start: 2004-07-31End: 2006-01-31Target: 190Updated: 2011-01-27

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

WithdrawnNCT00233636

AstraZenecaCarcinoma, Squamous Cell, Head and Neck Cancer

Start: 2003-07-31Target: 28Updated: 2011-01-27

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

TerminatedNCT00234442

AstraZenecaBrain Neoplasms, Non Small Cell Lung Cancer

Start: 2004-07-31End: 2006-02-28Target: 47Updated: 2009-06-30

Phase 3

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

TerminatedNCT00234468

AstraZenecaNon Small Cell Lung Carcinoma

Start: 2004-01-31End: 2007-08-31Target: 490Updated: 2011-05-20

Related Papers

Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).

2012-08-0122 citations